Stein Natan, Tsukerman Pinchas, Mandelboim Ofer
Hum Antibodies. 2017;25(3-4):111-119. doi: 10.3233/HAB-160307.
One of the most exciting fields in modern medicine is immunotherapy, treatment which looks to harness the power of the immune system to fight disease. A particularly effective strategy uses antibodies designed to influence the activity levels of the immune system. Here we look at two receptors - TIGIT and DNAM-1 - which bind the same ligands but have opposite effects on immune cells, earning them the label `paired receptors'. Importantly, natural killer cells and cytotoxic T cells express both of these receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. In this review we present cases in which the modulation of these receptors holds potential for the development of novel therapies.
现代医学中最令人兴奋的领域之一是免疫疗法，即一种借助免疫系统的力量来对抗疾病的治疗方法。一种特别有效的策略是使用旨在影响免疫系统活性水平的抗体。在这里，我们研究两种受体——TIGIT和DNAM-1，它们结合相同的配体，但对免疫细胞具有相反的作用，因此被称为“配对受体”。重要的是，自然杀伤细胞和细胞毒性T细胞都表达这两种受体，在某些情况下，它们的效应功能由TIGIT或DNAM-1信号传导决定。靶向TIGIT或DNAM-1的激动剂和拮抗剂抗体为从癌症到自身免疫性疾病等多种疾病提供了许多治疗选择。在这篇综述中，我们介绍了调节这些受体在开发新疗法方面具有潜力的案例。
